Search

The dopamine receptor in the intermediate lobe (IL) of the hypophysis of the rat is characterized on the basis of the ability of dopamine and other dopaminergic agonists to decrease the consequences of activation of the beta-adrenoceptor. Stimulation of the dopamine receptor diminishes the L-isoproterenol-induced accumulation of cAMP and the catecholamine-stimulated enhancement of adenylate cyclase activity. The dopamine receptor in the IL can be assigned to the category of dopamine receptor designated D-2 on the basis of the following criteria: 1) occupancy of the dopamine receptor does not result in enhancement of adenylate cyclase activity or an accumulation of cAMP, 2) the dopaminergic ergots and apomorphine mimic the inhibitory effect of dopamine upon cAMP formation or alpha MSH release, and 3) metoclopramide and sulpiride, substituted benzamides, block the inhibitory effect of dopamine. The sympathetic neurotransmitter, norepinephrine, interacts with the dopamine receptor and the beta-adrenoceptor in the IL.

After treatment with cholera toxin, homogenates of intact intermediate lobe (IL) tissue of rat pituitary gland synthesized more cAMP than did homogenates of untreated IL tissue, and only in the presence of GTP did dopamine or apomorphine diminish the elevated adenylate cyclase activity in homogenates of cholera toxin-treated IL tissue. Furthermore, when tested on cholera toxin-treated IL tissue, 5'-guanylyl imidodiphosphate [Gpp(NH)p] and two other nonhydrolyzable analogs of GTP inhibited adenylate cyclase activity in the absence of either a dopaminergic agonist or GTP; GTP reversed the Gpp(NH)p-induced inhibition of adenylate cyclase activity. Apomorphine, a dopaminergic agonist, abolished the ability of GTP to reverse the inhibition by Gpp(NH)p; this effect of apomorphine was prevented by fluphenazine, a dopaminergic antagonist. Sodium fluoride inhibited adenylate cyclase activity to approximately the same level obtained with GTP and apomorphine. In addition, apomorphine decreased cAMP accumulation and alpha MSH release from dispersed IL cells pretreated with cholera toxin.

The intermediate lobe (IL) of the rat pituitary gland responds to catecholamines. Catecholamines interacting with the beta-adrenoceptor stimulate adenylate cyclase activity, enhance cyclic AMP formation and thereby trigger the release of alpha-melanocyte-stimulating hormone (alpha-MSH). Catecholamines interacting with a D-2 dopamine receptor (in the classification schema of Kebabian and Calne) diminish adenylate cyclase activity and thereby decrease the capacity of IL cells to synthesize cyclic AMP. Dopaminergic agonists also inhibit the release of alpha-MSH from IL cells. The homogeneity of the IL facilitates biochemical investigations of this tissue.

In experiments using a cell-free homogenate of the intermediate lobe of the hypophysis of the rat, apomorphine, a dopaminergic agonist, diminished both basal and L-isoproterenol-stimulated adenylate cyclase activity; dopaminergic antagonists from several chemical families reversed these inhibitory effects of apomorphine. Apomorphine diminished the ability of GTP to enhance both basal and L-isoproterenol-stimulated adenylate cyclase activity but did not directly interfere with the interaction between the beta-adrenoceptor and L-isoproterenol. The affinity of the D-2 dopamine receptor in the intermediate lobe for each dopaminergic antagonist used in this study was estimated from a mathematical analysis of the data. (Endocrinology 108: 420, 1981)

Stimulation of the D-2 dopamine receptor inhibits pro-opiomelanocortin (POMC) synthesis in isolated rat intermediate lobe tissue. Intermediate lobe tissue was incubated in the absence or presence of various dopaminergic compounds, and then its capacity to incorporate [3H]tyrosine into POMC was tested. D-2 dopaminergic agonists caused a dose-dependent inhibition of POMC synthesis; the maximal inhibitory effect was approximately a 50% reduction in the amount of POMC synthesized. D-2 dopaminergic antagonists blocked the inhibitory effect of each agonist. Pretreatment of the tissue with pertussis toxin abolished the D-2 dopaminergic inhibition of POMC synthesis. The potency of pertussis toxin in abolishing the dopaminergic inhibition of POMC synthesis corresponded to its potency in abolishing the D-2 dopaminergic inhibition of adenylate cyclase activity. Cholera toxin, forskolin, and 8-bromo-cAMP, compounds that activate the cAMP pathway, enhanced the capacity of intermediate lobe tissue to synthesize POMC and counteracted the dopaminergic inhibition of POMC synthesis. Incubation of intermediate lobe tissue for 24 h with bromocriptine, a D-2 dopaminergic agonist, decreased the POMC mRNA content by 46% as determined by hybridization of RNA to a 32P-labeled probe. Incubation of intermediate lobe tissue with forskolin increased the level of POMC mRNA; incubation of the tissue with a combination of bromocriptine and forskolin also resulted in an increase in the level of POMC mRNA. It is proposed that Ni, the inhibitory guanyl nucleotide binding protein, and possibly adenylate cyclase mediate the dopaminergic inhibition of POMC synthesis.

The D-2 dopamine receptor mediates inhibition of adenylate cyclase in rat intermediate lobe; this receptor is linked to cyclase by the inhibitory guanyl nucleotide-binding protein (Ni). The functioning of components in the inhibitory system was compared in control and pertussis toxin-treated tissues. (-)-N-n-Propylnorapomorphine ((-)-NPA), a dopamine agonist, and 5'-guanylyl imidodiphosphate (Gpp(NH)p), a nonhydrolyzable GTP analog, caused a dose-dependent inhibition of adenylate cyclase in control tissue. Pertussis toxin abolished dopamine receptor-mediated inhibition of adenylate cyclase but did not alter Gpp(NH)p-induced inhibition of cyclase. In control tissue, GTP blocked Gpp(NH)p inhibition of cyclase in the absence, but not in the presence of (-)-NPA. Following pertussis toxin treatment, GTP blocked the inhibitory effect of Gpp(NH)p either in the absence or in the presence of (-)-NPA. Pertussis toxin did not alter the number of dopamine receptors or the affinity of the receptor for [3H]spiroperidol, a dopamine antagonist. However, pertussis toxin decreased the potency of (-)-NPA in the binding assay and abolished the ability of GTP to affect agonist binding. Furthermore, pertussis toxin abolished the dopamine receptor-mediated inhibition of immunoreactive alpha-melanocyte-stimulating hormone release, and induced the ADP-ribosylation of the Mr = 41,000 subunit of Ni.

[3H]Spiroperidol ([3H]SPIRO) binds with high affinity (Kd = 0.3 nM) to cell-free homogenates of the neurointermediate lobe of the rat pituitary gland. The neurointermediate lobe contains 19.2 fmol of specific binding sites, 86% of which occur in the intermediate lobe (IL). Compounds active upon the D-2 dopamine receptor in the IL compete with [3H]SPIRO for occupancy of the specific binding site. Guanosine 5'-triphosphate decreases the affinity of agonists, but not antagonists, for the specific binding site. For each drug tested, methods derived from competitive enzyme kinetics were used to calculate the apparent affinity constants of the drug for the binding site and for the receptor regulating adenylate cyclase activity. The pharmacological properties of the specific [3H]SPIRO binding site were compared to the pharmacological properties of the D-2 dopamine receptor inhibiting adenylate cyclase activity in the IL. The similarity between the affinities determined from the binding and enzyme assays suggests that some or all of the specific [3H]SPIRO binding sites in the IL are D-2 dopamine receptors inhibiting adenylate cyclase activity.

Stimulation of the D-2 dopamine receptor in the intermediate lobe (IL) of the rat pituitary gland diminishes both basal and isoproterenol-stimulated adenylate cyclase activity. Cholera toxin increases IL adenylate cyclase activity and reduces the ability of beta-adrenergic agonists to further enhance enzyme activity but does not alter the functioning of the D-2 dopamine receptor. Indeed, cholera toxin-treated IL tissue provides a useful experimental system to investigate the involvement of guanyl nucleotides in the functioning of the IL D-2 dopamine receptor. GTP is obligatory for dopaminergic agonists to inhibit adenylate cyclase activity of cholera toxin-treated IL tissue. Furthermore, 5'-guanylyl imidodiphosphate (Gpp[NH]p), a nonhydrolyzable analog of GTP, inhibits adenylate cyclase activity in the absence of a dopaminergic agonist. GTP reverses the Gpp(NH)p-induced inhibition of adenylate cyclase activity; apomorphine, a dopaminergic agonist, abolishes this effect of GTP. It is hypothesized that the D-2 dopamine receptor in the IL interacts with an inhibitory guanyl nucleotide component (Ni); stimulation of the D-2 dopamine receptor alters the properties of Ni so that Ni can interact with GTP and inhibit adenylate cyclase activity.